What is Twinrix?
The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents include recommendations on the use of Twinrix in people with HIV.
What should I tell my health care provider before receiving Twinrix?
Before receiving Twinrix, tell your health care provider:
- If you are allergic to yeast or any other ingredients in Twinrix, latex, or any medicines. Tell your health care provider if you have ever had any reactions to a previous of the vaccine or to any other HAV and HBV vaccines.
- About any medical conditions you have or have had, for example, or problems.
- If you are pregnant or plan to become pregnant. Whether Twinrix can harm an unborn baby is unknown. Talk to your health care provider about possible risks with taking Twinrix when pregnant.
- If you are breastfeeding or plan to breastfeed. Do not breastfeed if you have HIV.
- About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Twinrix may affect the way other medicines or products work, and other medicines or products may affect how Twinrix works. Ask your health care provider if there are interactions between Twinrix and the medicines you take.
Ask your health care provider about possible side effects from Twinrix. Your health care provider will tell you what to do if you have side effects.
How is Twinrix given?
A health care provider gives the Twinrix vaccine. The vaccine is injected into a muscle in the arm.with Twinrix is usually given as a series of either three or four vaccine shots over a 6- to 12-month period. Read any printed information that your health care provider gives you about the HAV and HBV ( ) vaccine (Twinrix).
Where can I find more information about Twinrix?
More information about the HAV and HBV (recombinant) vaccine (Twinrix) is available:
- Recommendations on the use of the HAV and HBV (recombinant) vaccine (Twinrix) in people with HIV, from the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by the , the , and the HIV Medicine Association of the Diseases Society of America
- Research studies related to the HAV and HBV (recombinant) vaccine (Twinrix), from
The above Patient Version drug summary is based on the following FDA label(s): Injection, suspension.
Last Reviewed: January 29, 2019